The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis.

[1]  M. Ito,et al.  Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study) , 2016, Osteoporosis International.

[2]  M. Ito,et al.  The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT , 2013, Osteoporosis International.

[3]  T. Tomomitsu,et al.  Diagnostic criteria for primary osteoporosis: year 2012 revision , 2013, Journal of Bone and Mineral Metabolism.

[4]  M. Fukunaga,et al.  Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. , 2011, Bone.

[5]  S. Boonen,et al.  Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  H. Genant,et al.  Effect of monthly ibandronate on hip structural geometry in men with low bone density , 2011, Osteoporosis International.

[7]  P. Roschger,et al.  Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  C. Graeff,et al.  Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Atsushi Harada,et al.  Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women. , 2010, Bone.

[10]  S. Boonen,et al.  Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial , 2010, Osteoporosis International.

[11]  S. Berney,et al.  Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis , 2008 .

[12]  John P. Bilezikian,et al.  One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis , 2006 .

[13]  Sundeep Khosla,et al.  Population‐Based Study of Age and Sex Differences in Bone Volumetric Density, Size, Geometry, and Structure at Different Skeletal Sites , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  H. Genant,et al.  Cortical and Trabecular Bone Mineral Loss From the Spine and Hip in Long‐Duration Spaceflight , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[16]  H K Genant,et al.  Structural Adaptation to Changing Skeletal Load in the Progression Toward Hip Fragility: The Study of Osteoporotic Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  Hajime Orimo,et al.  Diagnostic criteria for primary osteoporosis: year 2000 revision , 2001, Journal of Bone and Mineral Metabolism.